Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Denali Therapeutics Inc. - Common Stock
(NQ:
DNLI
)
21.08
+1.06 (+5.29%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Denali Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 08, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
↗
January 02, 2024
Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today.
Via
InvestorPlace
The Latest Analyst Ratings for Denali Therapeutics
↗
December 13, 2023
Via
Benzinga
Where Denali Therapeutics Stands With Analysts
↗
November 08, 2023
Via
Benzinga
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 07, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Analyst Expectations for Denali Therapeutics's Future
↗
August 31, 2023
Via
Benzinga
Where Denali Therapeutics Stands With Analysts
↗
August 10, 2023
Via
Benzinga
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
↗
November 03, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
↗
September 06, 2023
B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a
Via
Benzinga
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
August 30, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Analyst Expectations for Denali Therapeutics's Future
↗
June 21, 2023
Within the last quarter, Denali Therapeutics (NASDAQ:DNLI) has observed the following analyst ratings:
Via
Benzinga
Why Shares of Denali Therapeutics Are Up Monday
↗
May 15, 2023
Analysts maintained their buy ratings on the clinical-stage biotech company.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
↗
September 06, 2023
Via
Benzinga
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Where Denali Therapeutics Stands With Analysts
↗
April 12, 2023
Via
Benzinga
Where Denali Therapeutics Stands With Analysts
↗
March 02, 2023
Via
Benzinga
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
↗
June 29, 2023
With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend.
Via
InvestorPlace
Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker
↗
June 20, 2023
Denali Therapeutics Inc (NASDAQ: DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 IDS in children with
Via
Benzinga
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
June 20, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
↗
June 05, 2023
Via
Benzinga
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
May 18, 2023
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Via
MarketBeat
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 08, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Biogen Moves Deeper In Alzheimer's With Denali
↗
April 14, 2023
Biogen exercised their rights to a Denali Alzheimer's drug. What does this mean longer term to the field and the companies?
Via
Talk Markets
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
April 12, 2023
Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
April 10, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
February 27, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study
↗
February 23, 2023
Via
Benzinga
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
February 22, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
3 More Mid-Cap Biotechs The Street Sees Doubling
February 22, 2023
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.
Via
MarketBeat
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
February 15, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
